FDA panel to consider loosening regulations for some peptides

FDA advisers are meeting to decide whether compounding pharmacies can legally make seven unapproved peptides for prescription use — a yes wouldn’t be the same as FDA approval.
Interest in peptides like BPC‑157 has surged thanks to influencers, but most lack robust human testing and are often bought on a risky “gray market.”
HHS Secretary Robert F. Kennedy Jr. has praised and used these therapies, while experts warn of bias, contamination risks, and urge patients to consult doctors.